May 02, 2026 a 11:31 am
MDT: Dividend Analysis - Medtronic plc
Medtronic plc presents a stable dividend profile with a rich history of dividend payments stretching over 45 years. Its current yield of 3.26% is competitive within its sector, and the company shows a pattern of consistent if modest growth in dividend payouts. Medtronic's commitment to returning value to shareholders is evident, despite industry challenges and market fluctuations.
📊 Overview
Medtronic plc operates in a competitive sector driven by innovation and healthcare needs, presenting a robust dividend yield complemented by consistent dividend payments over decades. This showcases the company's strong resilience and stable financial strategy.
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Dividend yield | 3.26 % |
| Current dividend per share | 2.79 USD |
| Dividend history | 45 years |
| Last cut or suspension | None |
📉 Dividend History
Medtronic's longstanding history of dividend payments exemplifies its commitment to delivering shareholder value. This historic consistency is critical as it fosters investor confidence, particularly in volatile market conditions.
| Year | Dividend Per Share |
|---|---|
| 2026 | 0.71 |
| 2025 | 2.83 |
| 2024 | 2.79 |
| 2023 | 2.75 |
| 2022 | 2.67 |
📈 Dividend Growth
Analyzing the growth of dividends is crucial for assessing a company's future payout potential. Medtronic's dividend growth, albeit modest, suggests a commitment to long-term value enhancement.
| Time | Growth |
|---|---|
| 3 years | 1.96 % |
| 5 years | 4.42 % |
The average dividend growth is 4.42% over 5 years. This shows moderate but steady dividend growth.
✅ Payout Ratio
Payout ratios provide insight into dividend sustainability. They reflect the proportion of earnings paid out as dividends and are crucial for evaluating the company's long-term investment potential.
| Key figure ratio | Value |
|---|---|
| EPS-based | 77.57 % |
| Free cash flow-based | 66.25 % |
The EPS-based payout ratio of 77.57% suggests that the company distributes a significant portion of its earnings as dividends, which may limit future growth if not managed prudently. However, the FCF-based ratio of 66.25% indicates good coverage from cash flow, supporting dividend sustainability.
💰 Cashflow & Capital Efficiency
The analysis of cash flows and capital efficiency is vital in understanding a company's ability to generate cash and optimize capital. Metrics like Free Cash Flow Yield and CAPEX to Operating Cash Flow serve as indicators of operational and financial health.
| Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Free Cash Flow Yield | 4.79% | 4.91% | 3.79% |
| Earnings Yield | 4.31% | 3.47% | 3.11% |
| CAPEX to Operating Cash Flow | 25.74% | 23.38% | 24.16% |
| Stock-based Compensation to Revenue | 1.28% | 1.21% | 1.14% |
| FCF / Operating Cash Flow Ratio | 73.61% | 76.62% | 75.84% |
Medtronic demonstrates stable cash flow management and capital efficiency, essential for financing dividends, capital expenditures, and potential growth investments.
📑 Balance Sheet & Leverage Analysis
Examining the balance sheet provides insights into financial stability and leverage, helping to ascertain the company's ability to meet long-term obligations.
| Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Debt-to-Equity | 0.59 | 0.50 | 0.47 |
| Debt-to-Assets | 0.31 | 0.28 | 0.27 |
| Debt-to-Capital | 0.37 | 0.33 | 0.32 |
| Net Debt to EBITDA | 2.88 | 2.89 | 2.62 |
| Current Ratio | - | - | - |
| Quick Ratio | 1.42 | 1.55 | 1.81 |
| Financial Leverage | 1.91 | 1.79 | 1.77 |
While Medtronic maintains moderate levels of leverage, its decreasing debt ratios and strong liquidity cushion reflect a solid capability to withstand financial fluctuations.
🏦 Fundamental Strength & Profitability
Interpreting profitability and core financial ratios is vital for assessing the strategic orientation and improvement in efficiency, profitability, and shareholder value.
| Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Return on Equity | 9.71% | 7.32% | 7.30% |
| Return on Assets | 5.08% | 4.09% | 4.13% |
| Net Margin | 13.90% | 11.36% | 12.03% |
| EBIT Margin | 18.96% | 17.17% | 19.21% |
| EBITDA Margin | 27.49% | 25.35% | 27.85% |
| Gross Margin | 65.32% | 65.34% | 65.67% |
| R&D to Revenue | 8.15% | 8.45% | 8.63% |
Medtronic showcases a commendable return on equity and solid margins, indicative of operational efficiency and strategic investment in innovation.
💹 Price Development
🔍 Dividend Scoring System
| Category | Score | Indicator |
|---|---|---|
| Dividend yield | 4 | |
| Dividend Stability | 5 | |
| Dividend growth | 3 | |
| Payout ratio | 4 | |
| Financial stability | 4 | |
| Dividend continuity | 5 | |
| Cashflow Coverage | 4 | |
| Balance Sheet Quality | 5 |
Total Score: 34/40
🗣️ Rating
Medtronic plc is rated highly for its consistent dividend history, manageable payout ratios, and strong financial stability. While dividend growth is moderate, the firm's ability to sustain and potentially enhance payouts over time makes it a solid choice for investors seeking reliable income and stability in the healthcare sector.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years